CTNMContineum Therapeutics, Inc.
$13.21+16% 1Y
$13.21
$9.1752 weeks$17.56
CTNM as reported
Contineum Therapeutics, Inc. reported $0 of revenue over the trailing twelve months. 6 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q4 2024 · every figure below is as filed, with no scoring applied
- Net income
- −$58M
Net income · +1.2% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$53M
Free cash flow · +14% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q4 2024 · 6 quarters behind |
| Net income | −$58M | +1.2% | Q2 2026 |
| EPS | −$2.21 | n/a | Q2 2025 · 4 quarters behind |
| ROE | −26% | n/a | Q2 2026 |
| ROA | −25% | n/a | Q2 2026 |
| Free cash flow | −$53M | +14% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Contineum Therapeutics, Inc. (CTNM) · Revenue and profitRevenue and profitContineum Therapeutics, Inc. (CTNM)
RevenueNet incomeTrailing twelve months
Powered byryufin.com
Biotechnology
The closest names by size in the same industry